Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2012-11-15 Board/Management Inform…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCT CEO Dr Andrea Grant appointed Managing Director 2 pages 44.1KB
Board/Management Information Classification · 95% confidence The document is a company announcement dated 16 November 2012, regarding the appointment of Dr Andrea Grant as Managing Director of Living Cell Technologies Limited. It details her background, achievements, and the impact on the board composition. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no legal proceedings, no capital changes, and no report attachments. The content is focused on management changes at the board level. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 6258 characters, which is sufficient for a detailed announcement but does not contain financial statements or other report types. Confidence is high given the clear focus on management appointment.
2012-11-15 English
Chairman's Address to the 2012 Annual General Meeting 2 pages 42.7KB
AGM Information Classification · 95% confidence The document is a Chairman's address delivered at an Annual General Meeting (AGM) held on 16 November 2012. It discusses the company's progress, clinical trial milestones, partnerships, funding, and strategic outlook. The content is typical of presentations or speeches given during an AGM to shareholders, focusing on business updates and future plans rather than detailed financial statements or regulatory disclosures. The document length is relatively short (3739 characters), and it is clearly a speech or presentation rather than a formal report or announcement. Therefore, the most appropriate classification is AGM Information (AGM-R).
2012-11-15 English
AGM Presentation 24 pages 850.7KB
AGM Information Classification · 95% confidence The document is titled 'Consolidation & Acceleration CEO REPORT AGM 2012' and contains detailed information about the company's products, clinical trials, management, board, financials, and future goals. It is presented by the CEO and includes forward-looking statements, clinical data, and strategic plans. The presence of the term 'AGM 2012' and the nature of the content, which is typical for presentations or reports shared at an Annual General Meeting, strongly indicates this is material prepared for an AGM. The document is about 14,000 characters long, which is consistent with a presentation or report for an AGM rather than a full Annual Report or financial filing. There is no indication that this is a full Annual Report (10-K), earnings release, or other regulatory filing. Therefore, the most appropriate classification is AGM Information (AGM-R).
2012-11-15 English
Results of 2012 Annual General Meeting 2 pages 30.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a company announcement titled 'Results of the Annual General Meeting held on 16 November 2012'. It provides detailed voting results for resolutions passed at the AGM, including adoption of the Remuneration Report and re-election of a director. The content focuses on the official results of shareholder votes at the AGM, referencing specific resolutions and proxy instructions. The document length is 3648 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM presentation or annual report. There is no detailed financial data or management discussion, so it is not an Annual Report (10-K) or Management Report (MDA). It is not a Proxy Solicitation (PSI) or Remuneration Information (DEF 14A) report itself, but rather the results of voting on such matters. Therefore, the document best fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2012-11-15 English
Change of Director's Interest Notice 2 pages 74.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in shareholding, including the number of shares held before and after the transaction, the date of change, and the nature of the transaction (on-market trade). This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is 3460 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, earnings release, or any other type of filing. Therefore, the correct classification is Director's Dealing (DIRS).
2012-11-04 English
Six reasons to invest in LCT 11 pages 4.1MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Living Cell Technologies, focusing on the company's mission, product pipeline, partnerships, clinical development stages, financial snapshot, and management team. It includes forward-looking statements and is structured as an investor-oriented presentation with slides and images (not shown here). There are no financial statements, regulatory filings, or audit information. The content is typical of an investor presentation aimed at providing strategic and financial insights to potential investors. Therefore, the document fits best into the 'Investor Presentation' category (IP). The document length (10801 characters) and detailed content support this classification with high confidence.
2012-11-01 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.